You just read:

EU Regulatory Authorities Grant Orphan Status to Eisai's Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

News provided by

Eisai Europe Limited

07 May, 2013, 00:01 BST